MAIA Biotechnology Reports Increased Losses and Revenue from Grant Income in Q2 2026

MAIA Biotechnology, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $7.9 million for the quarter, compared to a loss of $5.3 million in the same period last year, marking a 49% increase in losses. For the first half of 2026, the net loss totaled $14.3 million, up from $9.9 million in the first half of 2025, reflecting a 45% year-over-year increase. The company's total operating expenses for the second quarter reached $8.3 million, a 61% increase from $5.2 million in the prior year, driven primarily by increased research and development costs.

In terms of revenue, MAIA reported $207,173 in grant income for the second quarter, a new addition to its financials, as the company had no revenue in the previous year. The increase in operating expenses was largely attributed to a rise in research and development expenditures, which surged by 81% to approximately $5.6 million, reflecting the company's ongoing clinical trials and scientific research efforts. General and administrative expenses also rose by 30% to $2.7 million, driven by higher investor relations and payroll costs.

Strategically, MAIA has made notable advancements in its clinical programs, particularly with its lead product candidate, ateganosine. The company has initiated a Phase 3 pivotal trial (THIO-104) for ateganosine in patients with advanced non-small cell lung cancer (NSCLC) and has expanded its clinical trial sites into the U.S. The company also completed a confidentially marketed public offering in March 2026, raising approximately $30 million, which is expected to fund ongoing clinical trials. As of June 30, 2026, MAIA had cash and cash equivalents of $27.6 million, a significant increase from $8.7 million at the end of 2025.

Operationally, MAIA has expanded its clinical trial footprint, with 44 active sites across six countries for its ongoing Phase 2 trial. The company has also activated multiple U.S. clinical sites for its trials, enhancing its patient recruitment capabilities. The total employee headcount has increased, reflecting the company's growth and expansion efforts. The company continues to rely on external funding to support its operations, as it has not yet achieved profitability and expects to incur operating losses in the foreseeable future.

Looking ahead, MAIA anticipates further developments in its clinical trials and plans to engage with regulatory authorities regarding the potential for accelerated approval of ateganosine. The company remains focused on advancing its pipeline and expanding its market presence, while also navigating the challenges of funding and operational execution in the biopharmaceutical landscape.